Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Light-Activated Enzymes Could Significantly Improve PCR-Based COVID-19 Diagnostic Tests

By LabMedica International staff writers
Posted on 16 Dec 2021

A new approach using enzymes triggered by light pulses could help to significantly improve COVID-19 diagnostic tests based on PCR. More...

The approach developed by biochemists at the Ludwig Maximilian University of Munich (LMU; Munich, Germany) is expected to help produce better enzymes for biotechnological and diagnostics use.

DNA polymerases and other enzymes that modify DNA are essential tools in biotechnology and diagnostics. They are the key component for COVID-19 diagnostics by PCR. As useful as they are, DNA processing enzymes often have important flaws. Some of them display significant activity during the preparation of the samples, while others have nasty secondary activities. Both can lead to loss of specificity and sensitivity, which has to be avoided in a diagnostic test.

The trick is to block any type of enzymatic activity until the assay starts. For diagnostics tests based on PCR, such as the above mentioned test for COVID-19, the solution is the development of a hot-start enzyme, which shows no activity until a high activation temperature is reached. The main drawback of these hot-start approaches is that they cannot be used for enzymes that are damaged by heat.

The researchers found a way around these problems by designing light-start enzymes. Their light-start enzymes are blocked until a pulse of UV light reactivates them. In their approach, the researchers bound a piece of DNA to the enzyme itself, which over-compete any other enzymatic substrates rendering the enzyme effectively inactive (including their secondary activities). The light pulse is used to cut the DNA attached to the enzyme resulting in a 100% active enzyme. The main advantage is that the mechanism should work for a broad range of DNA biding enzymes regardless of their specific way of action.

To prove their point the researchers produced four light-activatable versions of different DNA processing enzymes. Among them was the so called Phi29 DNA polymerase, an enzyme broadly used to amplify whole genomes but too heat-sensitive to be adapted to hot-start methods. Moreover, the team showed light-start PCR and proved that their DNA polymerases were as good or better compared to commercial hot-start enzymes for PCR.

“Light-controlled enzymes have been around for quite a while, but what makes our approach unique is that it can be applied to virtually any DNA processing enzyme. In the past you always needed very detailed information on how your enzyme works and you were never sure that you would come with a smart way to block the enzyme and reactivate it with light,” said LMU-biochemist Andrés Vera who led the project.

“This is definitely going to help to produce better enzymes for biotechnological and diagnostics use. Besides, current real-time PCR machines already incorporate light sources and they could be easily modified to bring these enzymes to the market anytime soon,” added Prof. Philip Tinnefeld at the Department of Chemistry of LMU.

Related Links:
Ludwig Maximilian University of Munich


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Online QC Software
Acusera 24•7
Thyroid Test
Anti-Thyroid EIA Test
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.